Hunan Jiudian Pharmaceutical Co., Ltd. Stock

Equities

300705

CNE1000034Z6

Pharmaceuticals

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-24 pm EDT 5-day change 1st Jan Change
35.01 CNY +2.67% Intraday chart for Hunan Jiudian Pharmaceutical Co., Ltd. +0.89% +5.36%
Sales 2024 * 3.53B 488M Sales 2025 * 4.43B 612M Capitalization 12.08B 1.67B
Net income 2024 * 495M 68.38M Net income 2025 * 639M 88.27M EV / Sales 2024 * 3.42 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.73 x
P/E ratio 2024 *
24.3 x
P/E ratio 2025 *
18.8 x
Employees 1,636
Yield 2024 *
0.51%
Yield 2025 *
0.63%
Free-Float 48.72%
More Fundamentals * Assessed data
Dynamic Chart
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Elects Yang Yang and Fan Pengyun as Non-Independent Director CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd.(XSEC:300705) added to S&P Global BMI Index CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Approves 2022 Final Profit Distribution, Payable on May 15, 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Proposes Cash Dividend for the Year of 2022 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hunan Jiudian Pharma Wins Nod to Trial Anti-Inflammatory Patch MT
Jiudian Pharma Sees FY22 Profit to Rise Up to 33.7% MT
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Announces Cash Dividend for A Shares for the Year 2021, Payable on 27 May 2022 CI
Hunan Jiudian Pharmaceutical Co., Ltd. Approves Cash Dividend for 2021 CI
More news
1 day+2.67%
1 week+0.89%
Current month-6.74%
1 month-4.86%
3 months+12.39%
6 months+43.31%
Current year+5.36%
More quotes
1 week
33.08
Extreme 33.08
36.63
1 month
33.08
Extreme 33.08
39.00
Current year
27.68
Extreme 27.68
39.00
1 year
18.80
Extreme 18.8
39.00
3 years
13.14
Extreme 13.1357
39.00
5 years
6.85
Extreme 6.85
39.00
10 years
4.44
Extreme 4.4429
39.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 02-12-31
Director of Finance/CFO 60 06-12-31
Director/Board Member 47 00-12-31
Members of the board TitleAgeSince
Chairman 61 00-12-31
Director/Board Member 60 00-12-31
Director/Board Member 57 00-12-31
More insiders
Date Price Change Volume
24-04-25 35.01 +2.67% 7,675,592
24-04-24 34.1 -1.33% 3,023,474
24-04-23 34.56 -4.24% 4,832,800
24-04-22 36.09 +4.58% 2,584,185
24-04-19 34.51 -0.55% 2,077,440

End-of-day quote Shenzhen S.E., April 24, 2024

More quotes
Hunan Jiudian Pharmaceutical Co Ltd is a company mainly engaged in research and development, production and sales of pharmaceutical preparations. The Company’s products are comprised of pharmaceutical preparations, raw materials, pharmaceutical excipients and plant extracts, including loxoprofen sodium gel ointment, ornidazole raw materials and preparations, dirithromycin raw materials and preparations, clindamycin phosphate tablets and so on. The products are used for the treatment of bacterial infections and anti-allergy. The Company sells its products to both domestic and international markets, including Europe, South Korea, India, Russia and South America.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
35.01
Average target price
-
Consensus

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300705 Stock